The U.S. Food and Drug Administration has asked manufacturers to add new labeling warnings for gonadotropin-releasing hormone (GnRH) agonists, mostly used to treat men with prostate cancer. The warnings would note the potential risk of heart disease and diabetes in men treated with these medications. Read more at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230334.htm.
© 2020 HealthCom Media
All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder